BB Biotech’s Alexion Pharmaceuticals ALXN Stock Holding History

BB Biotech’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$178M	Hold	1,314,428	–	–	4.47%	8
2018 Q4	$128M	Hold	1,314,428	–	–	4.1%	9
2018 Q3	$183M	Sell	1,314,428 -30,000	-2%	-$3.76M	4.84%	6
2018 Q2	$167M	Sell	1,344,428 -50,000	-4%	-$5.84M	4.82%	10
2018 Q1	$155M	Buy	1,394,428 +40,000	+3%	+$4.78M	4.3%	12
2017 Q4	$162M	Hold	1,354,428	–	–	4.56%	10
2017 Q3	$190M	Hold	1,354,428	–	–	5.26%	8
2017 Q2	$165M	Buy	1,354,428 +125,000	+10%	+$14.5M	5.04%	7
2017 Q1	$149M	Hold	1,229,428	–	–	4.88%	8
2016 Q4	$150M	Buy	1,229,428 +50,000	+4%	+$6.12M	5.57%	6
2016 Q3	$145M	Hold	1,179,428	–	–	5.08%	7
2016 Q2	$138M	Buy	1,179,428 +145,000	+14%	+$20.6M	5.44%	7
2016 Q1	$144M	Hold	1,034,428	–	–	5.72%	5
2015 Q4	$197M	Hold	1,034,428	–	–	5.56%	6
2015 Q3	$162M	Buy	1,034,428 +257,000	+33%	+$46.9M	5.13%	6
2015 Q2	$141M	Buy	777,428 +105,000	+16%	+$18.1M	3.81%	10
2015 Q1	$117M	Hold	672,428	–	–	3.47%	11
2014 Q4	$124M	Sell	672,428 -55,000	-8%	-$10.2M	4.03%	8
2014 Q3	$121M	Hold	727,428	–	–	4.9%	7
2014 Q2	$114M	Hold	727,428	–	–	5.4%	7
2014 Q1	$111M	Sell	727,428 -30,000	-4%	-$4.77M	5.7%	5
2013 Q4	$101M	Hold	757,428	–	–	5.38%	6
2013 Q3	$88M	Sell	757,428 -20,698	-3%	-$2.27M	4.79%	6
2013 Q2	$71.8M	Buy	+778,126	New	+$75M	5.17%	6

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BB Biotech's ALXN Position: Q1 2019 in Review

BB Biotech held its Alexion Pharmaceuticals (ALXN) position steady in Q1 2019 at 1,314,428 shares worth $178M. The position accounts for 4.47% of the portfolio, ranked #8.

BB Biotech first reported a position in ALXN in Q2 2013 and has held it in 24 quarters since. The position peaked at $197M in Q4 2015. 612 funds tracked by Wall St. Rank hold ALXN as of Q1 2019.

BB Biotech held 1,314,428 shares of Alexion Pharmaceuticals worth $178M as of Q1 2019.
BB Biotech left its Alexion Pharmaceuticals share count unchanged in Q1 2019.
Alexion Pharmaceuticals made up 4.47% of BB Biotech's portfolio in Q1 2019, its #8 holding.
BB Biotech first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 24 quarters since.
BB Biotech's Alexion Pharmaceuticals position peaked at $197M in Q4 2015.
612 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2019.

Based on BB Biotech's 13F filing for Q1 2019, filed 13 May 2019.